---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-036866"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2026-09-17T13:27:26+00:00"
generated_at: "2026-09-17T13:28:38.989731+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Lisata closes Marea reverse merger; $225M PIPE financing

## Summary
- Merger closed Sept 17, 2026; Marea stockholders get 1,793,129 LSTA shares + 211,365 Series C preferred (convertible to common).
- $225M PIPE: 150,867.995 Series C preferred shares sold to investors; expected close Sept 18, 2026.
- Post-deal ownership: LSTA legacy holders ~2.39%, Marea holders ~59.54%, PIPE investors ~38.07% (on conversion).
- Ted Love (ex-GBT CEO) joins board; Josh Lehrer (Marea CEO) named President & COO; Mazzo stays CEO.
- 180-day lock-up on insider shares; stockholder vote needed for Series C conversion and change of control.

## SEC filing metadata
- accession: 0001140361-26-036866
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2026-09-17T13:27:26+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 1.01, 5.03, 2.01, 3.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000114036126036866/0001140361-26-036866-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000114036126036866/ef20082158_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-036866
- JSON: https://secwatch.observer/filing/0001140361-26-036866.json
- Plain text: https://secwatch.observer/filing/0001140361-26-036866.txt

## Key facts
- Executive change
  David J. Mazzo resigned as President at LISATA THERAPEUTICS, INC..
  - Action: resigned
  - Role: President
  source text: Immediately prior to such appointment, David J. Mazzo, Ph.D. resigned solely from the office of President, but he retained his position as Chief Executive Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/320017/000114036126036866/0001140361-26-036866-index.htm
- Executive change
  Josh Lehrer was appointed as President and Chief Operating Officer at LISATA THERAPEUTICS, INC..
  - Action: appointed
  - Role: President and Chief Operating Officer
  source text: In accordance with the Merger Agreement, on September 17, 2026 , effective immediately after the First Effective Time, Josh Lehrer, M.D., M.Phil., FACC was appointed as the President and Chief Operating Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/320017/000114036126036866/0001140361-26-036866-index.htm
- Executive change
  Ted W. Love was appointed as Director at LISATA THERAPEUTICS, INC..
  - Action: appointed
  - Role: Director
  source text: In accordance with the Merger Agreement, on September 17, 2026 , effective immediately after the First Effective Time, Ted W. Love, M.D. was appointed to the Board as a director.
  evidence_url: https://www.sec.gov/Archives/edgar/data/320017/000114036126036866/0001140361-26-036866-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.